Multiple myeloma at diagnosis in non-frail patients

Carried by: Francophone Myeloma Intergroup

References:

Clinician(s): Pr Salomon MANIER

Biologist(s): Pr Jill CORE

Presentation

Presentation of the pre-indication:

5,500 new cases per year in France
Incurable disease requiring ongoing treatment
Five-year survival rate = 60%
Significant morbidity: bone, renal and haematological complications
Considerable prognostic heterogeneity, correlated with molecular heterogeneity: certain high-risk factors are well identified -> included in the NGS panels used in France (IMS/IMWG Consensus Recommendations, Avet-Loiseau et al. J Clin Oncol, 2025) and recommended by the HAS (opinion 17/10/2025).

However, 15% of standard-risk patients will relapse within 18 months.

Any patient with newly diagnosed myeloma for whom an NGS panel has been prescribed:

Eligible for therapeutic intensification (under 65 years of age) or elderly ‘fit’ subjects
Frozen samples available
- Sorted plasma cell DNA*: 2 µg
- Sorted plasma cell RNA*: 500 ng
- Peripheral blood for constitutional DNA

* Systematic CD138+ immunomagnetic bone marrow sorting, minimum purity 70%